National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Absolute risk

The probability of an event or outcome occurring in a defined population over a specified time period

Absolute risk reduction

A measure of treatment effect that compares the decrease in risk in the control group with that of a treatment group i.e. Pc – Pt

Adverse event

An undesirable effect of a health technology

Avatrombopag (Doptelet®). HTA ID: 20006

Avatrombopag is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure.


NCPE Assessment Process Complete
Rapid review commissioned 11/02/2020
Rapid review completed 02/04/2020
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that avatrombopag be considered for reimbursement*.


*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.

The HSE has approved reimbursement; September 2020